JGP Global Gestao de Recursos Ltda. bought a new position in Nevro Corp (NYSE:NVRO) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 4,189 shares of the medical equipment provider’s stock, valued at approximately $262,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NVRO. Paloma Partners Management Co bought a new stake in shares of Nevro in the 3rd quarter worth $310,000. BlueMountain Capital Management LLC bought a new stake in shares of Nevro in the 3rd quarter worth $413,000. Man Group plc bought a new stake in shares of Nevro in the 3rd quarter worth $1,083,000. MetLife Investment Advisors LLC grew its stake in shares of Nevro by 55.3% in the 3rd quarter. MetLife Investment Advisors LLC now owns 20,240 shares of the medical equipment provider’s stock worth $1,154,000 after acquiring an additional 7,210 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in shares of Nevro by 100.4% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 128,566 shares of the medical equipment provider’s stock worth $7,328,000 after acquiring an additional 64,406 shares in the last quarter.

A number of equities analysts recently weighed in on the stock. Canaccord Genuity boosted their price target on shares of Nevro from $46.00 to $62.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th. Morgan Stanley raised shares of Nevro from an “underweight” rating to an “overweight” rating and boosted their price target for the stock from $41.00 to $70.00 in a report on Wednesday, March 20th. Wells Fargo & Co raised shares of Nevro from a “market perform” rating to an “outperform” rating and set a $75.00 price target on the stock in a report on Wednesday, March 20th. Bank of America raised shares of Nevro from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $50.00 to $70.00 in a report on Wednesday, March 20th. Finally, BMO Capital Markets raised shares of Nevro from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $46.00 to $67.00 in a report on Tuesday, March 19th. Three research analysts have rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $62.67.

NYSE NVRO traded down $2.93 during trading on Wednesday, hitting $61.18. 993,351 shares of the company’s stock traded hands, compared to its average volume of 713,210. The company has a market cap of $2.00 billion, a PE ratio of -37.30 and a beta of 0.21. Nevro Corp has a 12-month low of $34.75 and a 12-month high of $94.34. The company has a quick ratio of 5.64, a current ratio of 7.11 and a debt-to-equity ratio of 0.62.

Nevro (NYSE:NVRO) last released its quarterly earnings data on Thursday, February 21st. The medical equipment provider reported ($0.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.15). The business had revenue of $107.90 million for the quarter, compared to analysts’ expectations of $107.39 million. Nevro had a negative net margin of 12.70% and a negative return on equity of 20.13%. Nevro’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period last year, the company earned ($0.15) earnings per share. As a group, equities research analysts anticipate that Nevro Corp will post -2.31 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2019/04/24/jgp-global-gestao-de-recursos-ltda-buys-new-position-in-nevro-corp-nvro.html.

Nevro Profile

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

See Also: Understanding the different types of bonds

Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp (NYSE:NVRO).

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.